Identification of a subtype selective human PPARα agonist through parallel-array synthesis-Reference-Cited by-同舟云学术

Identification of a subtype selective human PPARα agonist through parallel-array synthesis

Published:2001-05 Issue:9 Volume:11 Page:1225-1227
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Brown Peter J.,Stuart L.William,Hurley Kevin P.,Lewis Michael C.,Winegar Deborah A.,Wilson Joan G.,Wilkison William O.,Ittoop Olivia R.,Willson Timothy M.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference8 articles.

1. The PPARs: From Orphan Receptors to Drug Discovery

2. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

3. Peroxisome proliterator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging

4. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

5. A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of PPAR Ligands and Nanoparticle Technology in Metabolic Steatohepatitis Treatment;Biomedicines;2024-08-16

2. Prospective de novo drug design with deep interactome learning;Nature Communications;2024-04-22

3. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in mouse, rat, and pooled human hepatocytes;Toxicological Sciences;2024-04-04

4. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mouse hepatocytes;Toxicological Sciences;2024-04-04

5. Screening of Chelidonium majus isoquinoline alkaloids reveals berberine and chelidonine as selective ligands for the nuclear receptors RORβ and HNF4α, respectively;Archiv der Pharmazie;2024-03-19